GNLX vs. IMMP, ATAI, NKTR, VTYX, ALDX, RANI, RZLT, ACRV, OMER, and AKBA
Should you be buying Genelux stock or one of its competitors? The main competitors of Genelux include Immutep (IMMP), Atai Life Sciences (ATAI), Nektar Therapeutics (NKTR), Ventyx Biosciences (VTYX), Aldeyra Therapeutics (ALDX), Rani Therapeutics (RANI), Rezolute (RZLT), Acrivon Therapeutics (ACRV), Omeros (OMER), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical preparations" industry.
Genelux (NASDAQ:GNLX) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, dividends, valuation, analyst recommendations, profitability, risk, media sentiment, earnings and institutional ownership.
Immutep's return on equity of 0.00% beat Genelux's return on equity.
37.3% of Genelux shares are owned by institutional investors. Comparatively, 2.3% of Immutep shares are owned by institutional investors. 11.7% of Genelux shares are owned by company insiders. Comparatively, 3.1% of Immutep shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Genelux has a beta of -1.37, indicating that its stock price is 237% less volatile than the S&P 500. Comparatively, Immutep has a beta of 2.18, indicating that its stock price is 118% more volatile than the S&P 500.
Immutep has higher revenue and earnings than Genelux.
In the previous week, Genelux had 1 more articles in the media than Immutep. MarketBeat recorded 3 mentions for Genelux and 2 mentions for Immutep. Genelux's average media sentiment score of 1.46 beat Immutep's score of 0.35 indicating that Genelux is being referred to more favorably in the media.
Immutep received 301 more outperform votes than Genelux when rated by MarketBeat users. However, 100.00% of users gave Genelux an outperform vote while only 72.43% of users gave Immutep an outperform vote.
Genelux currently has a consensus price target of $32.33, suggesting a potential upside of 1,318.13%. Immutep has a consensus price target of $8.50, suggesting a potential upside of 218.35%. Given Genelux's higher possible upside, equities analysts plainly believe Genelux is more favorable than Immutep.
Summary
Genelux beats Immutep on 8 of the 14 factors compared between the two stocks.
Get Genelux News Delivered to You Automatically
Sign up to receive the latest news and ratings for GNLX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GNLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
